 Antiarrhythmic actions tocainide canine models previous myocardial infarction antiarrhythmic antifibrillatory efficacies class IB antiarrhythmic agent tocainide conscious dogs early subacute phase anterior myocardial infarction hours infarction anesthetized dogs ventricular tachyarrhythmias inducible programmed stimulation days anterior myocardial infarction frequency spontaneous premature ventricular complexes early subacute postinfarction phase total complexes cumulative intravenous administration mg/kg late postinfarction setting intravenous administration tocainide intravenous dose micrograms/kg/min intravenous maintenance infusion initiation ventricular tachyarrhythmias programmed stimulation animals rate tachycardia additional animals incidence ventricular fibrillation total number arrhythmia-related deaths occurrence secondary ischemic insult presence previous infarction tocainide incidence ventricular fibrillation total number arrhythmia-related deaths saline-vehicle control groups incidence ventricular fibrillation incidence total number arrhythmia-related deaths findings class agents tocainide efficacious suppression spontaneous premature ventricular complexes ventricular arrhythmias myocardial infarction limited value prevention malignant ischemic arrhythmias myocardial infarction